Category Archives: Transhuman News

Newswise By studying the genetic makeup of breast cancer patients, doctors are taking the next steps forward in delivering more personalized care to patients. Whole genome sequencing from cancers is not a new concept, but recently researchers have delved more deeply into the evolution of breast cancers identifying that it comes in four distinct types. Breaking down how the cells of each sub-type of the disease function is allowing for doctors to customize treatments for improved outcomes.

Even more promising, clinical research trials at a few select institutions around the country, including Clevelands University Hospitals Case Medical Center Seidman Cancer Center, are part of a development in a rising trend toward targeted treatments as a result of genomic profiling of tumors.

The knowledge of the molecular underpinnings of a particular kind of breast cancer can improve the cure rates and even in the advanced disease setting improve quality of life and length of life, says Lyndsay Harris, MD, Director, Breast Cancer Program, UH Seidman Cancer Center. The cure of the disease is really our goal, and we are moving quickly toward a time when we can expect to cure the vast majority of women who are diagnosed with breast cancer at the earliest stages.

Dr. Harris and her team are currently conducting a whole genome sequencing study to examine what changes in the tumor are unique to a breast cancer patient. The anticipated outcome is to determine who will benefit most from certain drug therapies and to use that information to create a personalized treatment plan for each patient involved.

Dr. Harris can be available in the University Hospitals broadcast studio by calling 216-844-2555.

Read more:
Rising Trend in Genome Mapping Delivers Targeted Breast Cancer Treatment

WASHINGTON - Little Amelia Sloan became a pioneer shortly after her birth.

The healthy baby is part of a large research project outside the nation's capital that is decoding the DNA of hundreds of infants. New parents in a few other cities soon can start signing up for smaller studies to explore what's called genome sequencing fully mapping someone's genes to look for health risks should become a part of newborn care.

It's full of ethical challenges.

Should parents be told only about childhood threats? Or would they also want to learn if their babies carried a key gene for, say, breast cancer after they're grown? Could knowing about future risks alter how a family treats an otherwise healthy youngster? And how accurate is this technology could it raise too many false alarms?

This is the newest frontier in the genetic revolution: how early to peek into someone's DNA, and how to make use of this health forecast without causing needless worry.

"This was something that was looming over the horizon," said Dr. Alan Guttmacher, a pediatrician and geneticist who heads the National Institutes of Health's child health division. Last month, NIH announced a $25 million, five-year pilot project in four cities Boston, San Francisco, Chapel Hill, N.C., and Kansas City, Mo. to start answering some of the questions before the technology is widely offered for babies.

Today, the 4 million U.S. babies born annually have a heel pricked in the hospital, providing a spot of blood to be tested for signs of at least 30 rare diseases. This newborn screening catches several thousand affected babies each year in time for early treatment to prevent death, brain damage or other disabilities. It's considered one of the nation's most successful public health programs.

A complete genetic blueprint would go well beyond what that newborn blood spot currently tells doctors and parents allowing a search for potentially hundreds of other conditions, some that arise in childhood and some later, some preventable and some not.

"If I truly believed that knowing one's genome was going to be transformative to medicine over the next decade or more, then wouldn't I want to start generating that information around the time of birth?" asked Dr. John Niederhuber, former director of the National Cancer Institute who now oversees one of the largest baby-sequencing research projects to date.

At Niederhuber's Inova Translational Medicine Institute in Falls Church, Va., researchers are mapping the genomes of newborns, along with their parents and other relatives for comparison. The long-term goal of the privately funded study is to uncover genetic patterns that predict complex health problems, from prematurity to developmental disorders.

More here:
Genome sequencing in babies raises ethical questions